NCT03715933 2026-03-18
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
Phase 1 Recruiting
Inhibrx Biosciences, Inc
Amgen
Saint John's Cancer Institute
Innovent Biologics (Suzhou) Co. Ltd.
Masonic Cancer Center, University of Minnesota